ArticleFrontiers in cardiovascular medicine2026
Application and efficacy evaluation of thoracoscopic techniques in ventricular tumors resection.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although fully thoracoscopic resection of atrial tumors has become well established, evidence supporting non-robotic fully thoracoscopic ventricular tumor resection remains limited, largely owing to the deep anatomical location of ventricular lesions, restricted operative space, and the complexity of subvalvular structures. Methods: We conducted a retrospective analysis of eight patients who underwent right-sided three-port fully thoracoscopic ventricular tumor resection between August 2022 and July 2025. Perioperative outcomes and near-term follow-up results were systematically evaluated. Results: All patients successfully underwent thoracoscopic tumor resection; one patient concurrently received tricuspid valve repair involving papillary muscle reattachment. Intraoperative transoesophageal echocardiography confirmed complete tumor excision in all cases. No major postoperative complications, including mortality or embolic events, were observed. The cardiopulmonary bypass time was (107 ± 64) min, and the aortic cross-clamp time was (49 ± 39) min. The mean intensive care unit stay was (21.5 ± 4.1) h, mechanical ventilation time was (16.4 ± 2.5) h, and postoperative hospital stay was (5 ± 1) days. No patient required postoperative allogeneic blood transfusion. Echocardiography before discharge and during follow-up demonstrated no residual tumors or significant valvular regurgitation. The mean follow-up duration was (21 ± 12) months, during which no tumor recurrence or distant metastasis was detected. Conclusion: A right-sided three-port fully thoracoscopic approach allows safe and controlled complete resection of ventricular tumors, with favourable perioperative recovery and near-to-mid-term outcomes. These findings suggest that this technique may represent a promising standardised minimally invasive alternative to conventional open surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.